Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240124 | 0.82 | LOXL2 (0.67) | LOXL2ADRB2PDPK1RAB9ANISCH | |
| SCHEMBL28230874 | 0.82 | ADRB2 (0.50) | LOXL2ADRB2PDPK1 | |
| SCHEMBL28230903 | 0.81 | LOXL2 (0.57) | LOXL2ADRB2PDPK1PLA2G4AHPGD | |
| SCHEMBL28861493 | 0.81 | LOXL2 (0.67) | LOXL2ADRB2PDPK1PLA2G4ACYP2A6 | |
| SCHEMBL4724672 | 0.81 | CYP2D6 (0.57) | LOXL2ADRB2PDPK1RAB9AKDM4E | |
| SCHEMBL722198 | 0.79 | PDPK1 (0.77) | LOXL2ADRB2PDPK1RAB9AALDH1A1 | |
| SCHEMBL3969950 | 0.79 | LOXL2 (0.73) | LOXL2ADRB2PDPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL17261482 | 0.79 | LOXL2 (0.62) | LOXL2ADRB2PDPK1RAB9ANPC1 | |
| SCHEMBL21791658 | 0.77 | LOXL2 (0.71) | LOXL2ADRB2PDPK1CYP2A6 | |
| SCHEMBL28230012 | 0.77 | ADRB2 (0.52) | LOXL2ADRB2PDPK1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399967-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2019-09-03 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399967-B2 | Compounds for inflammation and immune-related uses | CXCL8, CCR1, CCR8 | LOXL2 1305/4885ADRB2 1421/4885PDPK1 2077/4885 |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | LOXL2 1305/4885ADRB2 1421/4885PDPK1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.